关键词: Antifungal treatment Cigomicosis Isavuconazol Isavuconazole Mucormicosis Mucormycosis Tratamiento antifúngico Zygomycosis

Mesh : Humans Mucormycosis / diagnosis therapy

来  源:   DOI:10.1016/j.riam.2018.09.001   PDF(Sci-hub)

Abstract:
Infections due to zygomycetes, caused by mucorales and entomophthorales, are characterized by angioinvasion and invasion of neighboring organs or structures. Mucorales most commonly cause rhinocerebral, pulmonary, cutaneous or disseminated infection and its spread is favored by several diseases (such as diabetes or chronic kidney disease) and risk factors (neutropenia, immunosuppression, iron overload). They have a high mortality rate, and the key to success in their treatment are early diagnosis, prompt administration of antifungal treatment, and extensive surgical debridement. Currently, isavuconazole constitutes an option for the treatment of those mucormycosis refractory to liposomal amphotericin B. Due to its pharmacokinetic and pharmacodynamic characteristics and its low toxicity, it is also the best choice for maintenance therapy.
摘要:
合子菌感染,由粘液和昆虫引起,以血管浸润和邻近器官或结构的浸润为特征。粘液菌最常见的原因是鼻脑,肺,皮肤或播散性感染及其传播受到多种疾病(如糖尿病或慢性肾病)和危险因素(中性粒细胞减少症,免疫抑制,铁过载)。他们的死亡率很高,治疗成功的关键是早期诊断,及时服用抗真菌治疗,和广泛的手术清创术。目前,伊沙武康唑是治疗脂质体两性霉素B难治性毛霉菌病的一种选择。由于其药代动力学和药效学特征以及低毒性,也是维持治疗的最佳选择。
公众号